The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 136,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Cell & gene therapy in pharma: iPSCs. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s Technology Foresights, which uses over 730,000 patents to analyze innovation intensity for the pharmaceutical industry, there are 80+ innovation areas that will shape the future of the industry.
iPSCs is a key innovation area in cell & gene therapy
Induced pluripotent stem cells (iPSCs) are a type of stem cell that can be generated directly from adult cells, such as skin cells or blood cells, by using defined factors such as transcription factors. These cells can differentiate into any type of cell in the body, making them a potentially powerful tool for regenerative medicine.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 210+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of iPSCs.
Key players in iPSCs – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to iPSCs
| Company | Total patents (2021 - 2023) | Premium intelligence on the world's largest companies |
| Fujifilm | 175 | Unlock Company Profile |
| I'rom Group | 51 | Unlock Company Profile |
| Allele Biotechnology and Pharmaceuticals | 49 | Unlock Company Profile |
| Johnson & Johnson | 42 | Unlock Company Profile |
| Ministry of Trade and Industry, Singapore | 42 | Unlock Company Profile |
| BioNTech | 36 | Unlock Company Profile |
| Genesis Technologies | 35 | Unlock Company Profile |
| Taiga Biotechnologies | 34 | Unlock Company Profile |
| Cellscript | 34 | Unlock Company Profile |
| BioLamina | 33 | Unlock Company Profile |
| I Peace | 27 | Unlock Company Profile |
| Lonza Group | 26 | Unlock Company Profile |
| ReNeuron Group | 24 | Unlock Company Profile |
| Children's Medical Center | 21 | Unlock Company Profile |
| National Cancer Center | 20 | Unlock Company Profile |
| F. Hoffmann-La Roche | 20 | Unlock Company Profile |
| Kangstem Biotech | 20 | Unlock Company Profile |
| Mesoblast | 17 | Unlock Company Profile |
| Daiichi Sankyo | 15 | Unlock Company Profile |
| Mayo Clinic | 14 | Unlock Company Profile |
| Bristol-Myers Squibb | 13 | Unlock Company Profile |
| New World Laboratories | 13 | Unlock Company Profile |
| Megakaryon | 13 | Unlock Company Profile |
| Stemlab | 12 | Unlock Company Profile |
| Memorial Sloan Kettering Cancer Center | 11 | Unlock Company Profile |
| Touchlight Genetics | 11 | Unlock Company Profile |
| Hong Guan | 11 | Unlock Company Profile |
| Takara | 10 | Unlock Company Profile |
| Mclean Hospital | 10 | Unlock Company Profile |
| Scripps Health | 10 | Unlock Company Profile |
| TRON | 10 | Unlock Company Profile |
| Editas Medicine | 9 | Unlock Company Profile |
| Centre National de la Recherche Scientifique | 9 | Unlock Company Profile |
| Wellcome Trust | 8 | Unlock Company Profile |
| Cedars-Sinai Health System | 8 | Unlock Company Profile |
| Ibex Biosciences | 8 | Unlock Company Profile |
| GC | 8 | Unlock Company Profile |
| Orig3N | 7 | Unlock Company Profile |
| UAB Research Foundation | 7 | Unlock Company Profile |
| General Hospital | 7 | Unlock Company Profile |
| Riken | 6 | Unlock Company Profile |
| NEW HOPE, CITY OF | 6 | Unlock Company Profile |
| Max Planck Society | 6 | Unlock Company Profile |
| ReproCELL | 6 | Unlock Company Profile |
| Lyell Immunopharma | 5 | Unlock Company Profile |
| LifeSci Index Partners | 5 | Unlock Company Profile |
| Bayer | 5 | Unlock Company Profile |
| Novagenesis | 5 | Unlock Company Profile |
| Ono Pharmaceutical | 5 | Unlock Company Profile |
| Cerus | 4 | Unlock Company Profile |
Source: GlobalData Patent Analytics
I'rom Group, formerly I'rom Holdings, is a diversified company that offers contract research, clinical trials and regenerative medicine services. The company operates through four business segments. The Site Management Organization (SMO) segment provides support services for contracting or conducting clinical trials. The Contract Research Organization (CRO) segment provides clinical trial operations for pharmaceutical companies and others. The Advanced Medicinal Treatment segment is engaged in the development of gene therapy products, the development, manufacture and sale of products in the field of regenerative medicine based on iPS cells related technologies. The Medical Support segment provides general and comprehensive support for medical business management, such as setting up and renting clinic malls, selling products and related services.
Allele Biotechnology and Pharmaceuticals, and Johnson & Johnson are some of the other key patent filers in iPSCs.
In terms of application diversity, Megakaryon leads the pack, while Touchlight Genetics and Ono Pharmaceutical stood in the second and third positions, respectively.
By means of geographic reach, BioLamina held the top position, followed by F. Hoffmann-La Roche and Fujifilm.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
